Trellis Bioscience
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
702 Marshall St Ste 301, Redwood City, C...Phone Number
(408) 772-8049Website
www.trellisbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Trellis Bioscience
Trellis Bioscience specializes in the discovery and development of human monoclonal antibodies (mAbs) for the treatment of infectious diseases and cancer. Utilizing their proprietary CellSpot platform, they have developed a pipeline of products, including TRL1068, aimed at addressing complex medical challenges such as prosthetic joint infections and various viral infections. Their intended clients include healthcare providers and patients suffering from serious infections and cancer, with a focus on improving treatment outcomes and reducing the need for invasive procedures. The company is committed to advancing clinical evaluations and leveraging innovative technologies to enhance therapeutic options in the pharmaceutical industry.Explore more
Trellis Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Trellis Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Trellis Bioscience has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Trellis Bioscience
Trellis Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Trellis Bioscience has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Trellis Bioscience launches new products
Check out if Trellis Bioscience is spiking on competitors!
Click to see if Trellis Bioscience had a recent Job posting/layoffs
Earning: See what the market has to say on Trellis Bioscience recently announced quarterly report
Recommended Actions
Find VP level buyers at Trellis Bioscience
Find more new buyers
Compare Similar Companies to Trellis Bioscience
Compare insights from companies similar to Trellis Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$5.7M
11-50
Private
-
2001
Frank WilcoxChief Financial Officer, The Wholly-Owned Subsidiaries Universal Property & Casualty Insurance Company
Company Profile Activity
Activity Insights
Trellis Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Trellis Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Trellis Bioscience.
Trellis Bioscience financials insights
Gather financial insights about Trellis Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Series A
$3.4M
2007
Series B
$10M
2026
Private Equity
$6.1M
Trellis Bioscience Tech Stack
A closer look at the technologies used by Trellis Bioscience
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Project
Award, Spending/Investment, Clinical Operations, Operations
Funding
Project
Spending/Investment, Funding
Funding
Funding
Trellis Bioscience News & Media
Trellis Bioscience Announces Positive Interim Phase 1 Results for TRL1068, a Novel Native Human Monoclonal Antibody Which Reduces Bacterial Biofilm Burden in Chronic Prosthetic Joint Infections
Clinical proof-of-concept has been achieved for TRL1068 in a planned interim analysis based on completion of the second of three escalating dose groups 75% of chronic PJI patients treated with a single dose of TRL1068 and standard antibiotics had a bacterial biofilm burden below 100...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Trellis Bioscience
Sign Up For FreeTo access detailed company insights
Trellis Bioscience specializes in the discovery and development of human monoclonal antibodies (mAbs) for the treatment of infectious diseases and cancer. Utilizing their proprietary CellSpot platform, they have developed a pipeline of products, including TRL1068, aimed at addressing complex medical challenges such as prosthetic joint infections an... Read More
